A randomized phase II open label multi-institution study of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) in the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC).

被引：0
|
作者：
Thomas, Melanie B.
Garrett-Mayer, Elizabeth
Anis, Munazza
Anderton, Kate Robertson
Bentz, Tricia A.
Adelman, Andie Ray
Brisendine, Alan
Duddalwar, Vinay
Weiss, Geoffrey R.
Siegel, Abby B.
Bendell, Johanna C.
Baron, Ari David
El-Khoueiry, Anthony B.
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
[2] Hollings Canc Ctr Med Unit, Charleston, SC USA
[3] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[4] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Univ Virginia, Charlottesville, VA USA
[6] Columbia Univ, New York, NY USA
[7] PLLC, Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[8] Pacif Hematol Oncol Assoc, San Francisco, CA USA
[9] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.337
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
337
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma
    Thomas, Melanie B.
    Garrett-Mayer, Elizabeth
    Anis, Munazza
    Anderton, Kate
    Bentz, Tricia
    Edwards, Andie
    Brisendine, Alan
    Weiss, Geoffrey
    Siegel, Abby B.
    Bendell, Johanna
    Baron, Ari
    Duddalwar, Vinay
    El-Khoueiry, Anthony
    ONCOLOGY, 2018, 94 (06) : 329 - 339
  • [2] EFFICACY AND TOLERABILITY OF BEVACIZUMAB (B) AND ERLOTINIB (E) AS FIRST-LINE THERAPY IN ASIAN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A PHASE II TRIAL
    Hsu, C.
    Kang, Y.
    Yang, T. S.
    Su, W.
    Shun, C.
    Sandoval-Tan, J.
    Chiou, T.
    Jin, K.
    Hsu, C.
    Cheng, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 237 - 237
  • [3] A phase II study of bevacizumab (B) and erlotinib (E) in combination for Asian patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): An interim safety report
    Hsu, C.
    Kang, Y.
    Yang, T.
    Su, W.
    Sandoval-Tan, J.
    Chiou, T.
    Jin, K.
    Button, P.
    Hsu, C.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom M.
    Trojan, Jorg
    Cebon, Jonathan S.
    Liem, Andre K. D.
    Lipton, Lara Rachel
    Gupta, Charu
    Wu, Benjamin
    Litten, Jason B.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Zhu, A. X.
    Finn, R. S.
    Mulcahy, M. F.
    Gurtler, J. S.
    Sun, W.
    Schwartz, J. D.
    Rojas, P.
    Dontabhaktuni, A.
    Youssoufian, H.
    Stuart, K. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
    Hsu, Chih-Hung
    Kang, Yoon Koo
    Yang, Tsai-Shen
    Shun, Chia-Tung
    Shao, Yu-Yun
    Su, Wu-Chou
    Sandoval-Tan, Jennifer
    Chiou, Tzeon-Jye
    Jin, Kate
    Hsu, Chiun
    Cheng, Ann-Lii
    ONCOLOGY, 2013, 85 (01) : 44 - 52
  • [7] A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.
    Sangro, Bruno
    Park, Joong-Won
    Dela Cruz, Christine Marie
    Anderson, Jeffrey
    Lang, Lixin
    Neely, Jaclyn
    Shaw, James W.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
    Yau, Thomas
    Wong, Hilda
    Chan, Pierre
    Yao, T. J.
    Pang, R.
    Cheung, T. T.
    Fan, S. T.
    Poon, Ronnie T.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2384 - 2390
  • [9] Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
    Thomas Yau
    Hilda Wong
    Pierre Chan
    T. J. Yao
    R. Pang
    T. T. Cheung
    S. T. Fan
    Ronnie T. Poon
    Investigational New Drugs, 2012, 30 : 2384 - 2390
  • [10] COMBINATION OF BEVACIZUMAB AND ERLOTINIB IN THE TREATMENT OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WITH SORAFENIB-REFRACTORY DISEASE: RESULTS OF A PILOT PHASE II STUDY
    Yau, T.
    Wong, H.
    Chan, P.
    Yao, T. J.
    Cheung, T. T.
    Fan, S. T.
    Poon, R. T.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S1 - S2
12345